Annexon develops targeted immunotherapies for neuroinflammatory and classical complement-mediated diseases, with programs built around C1q and the classical complement pathway. Company news centers on clinical and regulatory progress for vonaprument in geographic atrophy, tanruprubart in Guillain-Barré syndrome, and ANX1502 as an oral C1 inhibitor for autoimmune disease.
Recurring updates also include quarterly financial results, research and development spending, cash runway disclosures, investor conference presentations, key opinion leader events, and equity inducement grants under Nasdaq rules. The company’s announcements connect pipeline progress with its balance sheet and public-company governance activity.
Annexon (ANNX) scheduled two vonaprument presentations for September 25, 2026, at The Retina Society’s annual meeting in Los Angeles.
One presentation covers baseline characteristics of participants in the ongoing Phase 3 ARCHER II trial and their similarity to those in Phase 2 ARCHER. The other covers a post hoc analysis of Phase 2 vision outcomes in eyes with subfoveal RPE lesions. Annexon expects month 15 ARCHER II results in the fourth quarter of 2026. The presentations are due on its publications page after the meeting.
Annexon (ANNX) granted equity inducement awards to two new non-executive employees under its 2022 Employment Inducement Award Plan, consistent with Nasdaq Listing Rule 5635(c)(4).
The awards were approved on September 12, 2026, and granted on September 15, 2026. In total, the employees received options to purchase 275,500 shares of Annexon common stock. The options have a 10-year term and an exercise price of $3.92 per share, equal to the closing price of Annexon common stock on the grant date. Vesting occurs over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% vesting in equal monthly installments over the following three years, subject to continued service.
Annexon (ANNX) will participate in three September 2026 healthcare investor conferences, featuring fireside chats with president and CEO Douglas Love.
Events include Wells Fargo on September 9 at 8:45 a.m. ET in Boston, Cantor on September 10 at 1:35 p.m. ET in New York, and H.C. Wainwright on September 15 at 1:00 p.m. ET in New York. Live and archived webcasts will be available on the company’s investor website.
Annexon (Nasdaq: ANNX) reported equity inducement grants to three new non-executive employees under its 2022 Employment Inducement Award Plan, consistent with Nasdaq Listing Rule 5635(c)(4). The awards were approved on August 10, 2026.
In total, the new hires received options to purchase 287,500 shares of Annexon common stock. According to Annexon, the stock options have a 10-year term and an exercise price of $5.29 per share, equal to the closing price on August 14, 2026, the grant date. The options vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining 75% vesting in equal monthly installments over the following three years, subject to continued service.
Annexon (Nasdaq: ANNX) reported second quarter 2026 results and major pipeline and financing updates. In GBS, tanruprubart showed early improvement in strength and disability in the first ten FORWARD study patients, supporting consistency with prior Phase 3 and real‑world data. An EU marketing application is under EMA review, and a U.S. BLA submission is expected in Q4 2026.
For GA, Phase 3 ARCHER II remains on track, now with dual primary endpoints at Months 15 and 24 and an open-label extension launched; the Month 15 readout is expected in Q4 2026 and final completion in Q3 2027. Annexon secured a credit facility of up to $200 million (initial $50 million drawn), held $209.2 million in cash, cash equivalents and short-term investments at June 30, 2026, and expects its runway to extend into 2028. Q2 2026 R&D and G&A expenses rose to $46.6 million and $10.6 million, respectively, with a net loss of $55.3 million, or $0.28 per share.
Annexon (Nasdaq: ANNX) has expanded its Phase 3 ARCHER II trial of vonaprument in dry age-related macular degeneration with geographic atrophy by adding a Month 24 dual primary endpoint to complement the existing Month 15 primary endpoint. This design allows independent assessment of vonaprument’s ability to protect against vision loss at either timepoint while the study remains masked through Month 24.
All eligible patients have received at least 12 months of treatment, with masked event accrual tracking projections, discontinuation <10% and compliance >95%. An open-label extension will offer monthly vonaprument after Month 24 to assess long-term safety and benefit. A DMC review of the Month 15 primary endpoint is expected in Q4 2026, with sub-study results anticipated in Q1 2027 if criteria are met, and overall completion including Month 24 analyses targeted for Q3 2027. Vonaprument holds FDA FastTrack, EMA PRIME status, and participation in EMA’s Product Development Coordinator pilot.
Annexon (Nasdaq: ANNX) appointed renowned retinal surgeon and biotechnology entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its board of directors, adding more than four decades of clinical, scientific and corporate leadership in retinal disease. Annexon also reported that long-serving director and investor Muneer Satter will step down from the board after more than 11 years of service.
According to Annexon, Dr. Blumenkranz’s expertise in retinal surgery, drug delivery, imaging and gene therapy, and his history of founding and leading multiple ophthalmic and life science companies, is expected to support the company as it advances vonaprument for geographic atrophy toward pivotal Phase 3 data and potential registration, and progresses its C1q‑targeted platform for neuroinflammatory diseases.
Annexon (Nasdaq: ANNX) reported early data from the first 10 U.S. and European patients with Guillain-Barré syndrome (GBS) in its ongoing open-label FORWARD study of tanruprubart. All patients showed rapid, clinically meaningful improvement in muscle strength within four days after a single 30 mg/kg infusion.
Four previously bedbound patients walked with or without assistance between days two and eight, and one ventilated patient was off ventilation within four days. Five other patients had marked functional gains within 48 hours. Tanruprubart was generally well-tolerated, with adverse events mainly related to GBS, and results were described as consistent with a prior Phase 3 study in which about 90% of patients improved by day 8. According to Annexon, FORWARD data are expected to support a planned BLA submission in Q4 2026, while a Marketing Authorisation Application is already under review by the EMA.
Annexon (Nasdaq: ANNX) entered a strategic credit facility with Oxford Finance for up to $200 million, expanding its financial capacity as vonaprument and tanruprubart advance toward registration. The facility is characterized by the company as non-dilutive capital to support potential global commercialization and long-term growth.
According to Annexon, it drew an initial $50 million at closing. An additional $100 million may become available upon achieving specified milestones in the vonaprument and tanruprubart registrational programs, with the remaining $50 million accessible subject to lender approval.
Annexon (Nasdaq: ANNX) granted equity inducement awards to two new non-executive employees under its 2022 Employment Inducement Award Plan, approved on July 12, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received stock options for an aggregate 335,000 common shares.
The options have a ten-year term and an exercise price of $6.50 per share, equal to the July 15, 2026 closing price. Vesting occurs over four years: 25% after one year, then 1/48 of the shares monthly, subject to continued service.